Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.

Experts in breast cancer share insights on the role of CDK4/6 inhibition in the adjuvant setting for early stage HR+ breast cancer.

Hope S. Rugo, MD, leads the discussion on the new data presented at the 2021 ASCO annual meeting for MammaPrint and Breast Cancer Index for early stage HR+ breast cancer.

The role of genomic assays, including Oncotype DX as reported on in the RxPONDER trial, for the optimal management of early stage HR+ breast cancer is discussed.

Aditya Bardia, MD, MPH, leads the discussion on the use of novel CDK4/6 inhibitors, BCL2 inhibitors, and oral SERDS for the treatment of HR+ metastatic breast cancer.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, review the optimal management of adverse events associated with alpelisib in HR+ metastatic breast cancer.

Breast cancer experts comment on whether there is a benefit to switching to or continuing on CDK4/6 inhibitors with disease progression for HR+ metastatic breast cancer and discuss the use of tamoxifen for third-line endocrine therapy.

Andrew D. Seidman, MD, presents a case study of a 56-year-old postmenopausal woman diagnosed with stage IIB HR+ breast cancer and leads the discussion on approaching treatment for the given patient.

Dejan Juric, MD, leads the discussion on the role of PIK3CA mutations in HR+ metastatic breast cancer.

Experts in breast cancer comment on the appropriate patient selection of CDK4/6 inhibitors for the management of HR-positive metastatic breast cancer.

A review of data from key phase 3 clinical trials, including ASCO 2021 updates, assessing the use of CDK4/6 inhibitors with endocrine therapy for the frontline treatment of HR-positive metastatic breast cancer.

Considerations for approaching the treatment of HR-positive metastatic breast cancer through insights on key prognostic factors.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss when it is appropriate to order molecular testing and the impact of testing on the treatment of HR-positive metastatic breast cancer.

A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.

Breast oncologists review the appropriateness for treating a patient with ER-positive, PR-positive, HER2-negative breast cancer with systemic therapy, with special considerations regarding sequencing therapy if using a CDK4/6 inhibitor as adjuvant therapy.

Andrew Seidman, MD, comments on results of the PRIME II study presented at SABCS and the appropriateness for radiation therapy in certain patient populations with HR-positive breast cancer.

Dr Massimo Cristofanilli, of the Feinberg School of Medicine, describes the PENELOPE-B study of palbociclib and endocrine therapy for patients with HR-positive breast cancer at high risk of relapse after neoadjuvant chemotherapy.

Dr Sara Tolaney comments on recent updates of the monarchE trial of abemaciclib and adjuvant endocrine therapy for high-risk early stage breast cancer as presented at SABCS 2020.

During a discussion regarding data demonstrated by the RxPONDER trial in HR-positive breast cancer, breast oncologists consider when ovarian suppression is most appropriate and for whom.

Dr Andrew Seidman reacts to outcomes of the RxPONDER trial of chemotherapy use in women with HR-positive breast cancer at low risk of recurrence.